Saturday 17 October 2026 Export RGC’s income statement to Excel — free account

Regencell Bioscience Holdings Limited

RGC Healthcare Drug Manufacturers Specialty & Generic

Dividend growth for three consecutive years.

9.59 0.07 +0.74%

Follow RGC

Alert me

Market cap: $4.7B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

	Older periods	Jun '23	Jun '24	Jun '25	Dec '25
ROE Full definition →	+7 more TTM periods Free account	(336.98%)	0.00%	0.00%	0.00%
ROA Full definition →		(207.77%)	0.00%	0.00%	0.00%
ROIC Full definition →		0.00%	0.00%	0.00%	0.00%
Return on Tangible Assets Full definition →		(112.86%)	0.00%	0.00%	0.00%
Free Cash Flow per Share Full definition →		0.00	0.00	0.00	0.00
Free Cash Flow Full definition →		(12.19)	(15.81)	(18.31)	(14.67)
Capital Expenditures Full definition →		(0.82)	(0.81)	(0.97)	—
Other line items
Cash ROIC Full definition →		(51.77%)	(97.72%)	(187.68%)	(410.18%)
Tax Rate Full definition →		0.00	—	—	—
Research and Development Expense of Revenue Full definition →		0.00%	—	—	—
Selling, General and Administrative Expense of Revenue Full definition →		0.00%	—	—	—
Operating CF/Net income Full definition →		0.84	0.00	0.00	0.00
Depreciation/Fixed assets Full definition →		0.53	0.84	0.77	0.00
Capex/Depreciation Full definition →		(1.70)	(1.05)	(1.17)	—
Revenue per Share Full definition →		0.00	—	—	—
Operating CF per Share Full definition →		0.00	0.00	0.00	0.00
Capex per Share Full definition →		0.00	0.00	0.00	—
Capex to Sales Full definition →		0.00	0.00	0.00	—

Show all line items

Columns are period end dates · fundamentals updated 9 Oct 2026